178 related articles for article (PubMed ID: 34789766)
1. SPME-LC/MS-based serum metabolomic phenotyping for distinguishing ovarian cancer histologic subtypes: a pilot study.
Olkowicz M; Rosales-Solano H; Kulasingam V; Pawliszyn J
Sci Rep; 2021 Nov; 11(1):22428. PubMed ID: 34789766
[TBL] [Abstract][Full Text] [Related]
2. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
[No Abstract] [Full Text] [Related]
3. Wide-Targeted Metabolome Analysis Identifies Potential Biomarkers for Prognosis Prediction of Epithelial Ovarian Cancer.
Hishinuma E; Shimada M; Matsukawa N; Saigusa D; Li B; Kudo K; Tsuji K; Shigeta S; Tokunaga H; Kumada K; Komine K; Shirota H; Aoki Y; Motoike IN; Yasuda J; Kinoshita K; Yamamoto M; Koshiba S; Yaegashi N
Toxins (Basel); 2021 Jun; 13(7):. PubMed ID: 34209281
[TBL] [Abstract][Full Text] [Related]
4. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.
Zhang F; Zhang Y; Ke C; Li A; Wang W; Yang K; Liu H; Xie H; Deng K; Zhao W; Yang C; Lou G; Hou Y; Li K
Metabolomics; 2018 Apr; 14(5):65. PubMed ID: 30830339
[TBL] [Abstract][Full Text] [Related]
5. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
Li J; Xie H; Li A; Cheng J; Yang K; Wang J; Wang W; Zhang F; Li Z; Dhillon HS; Openkova MS; Zhou X; Li K; Hou Y
Oncotarget; 2017 Jul; 8(29):46834-46845. PubMed ID: 27564116
[TBL] [Abstract][Full Text] [Related]
6. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry.
Zhang T; Wu X; Yin M; Fan L; Zhang H; Zhao F; Zhang W; Ke C; Zhang G; Hou Y; Zhou X; Lou G; Li K
Clin Chim Acta; 2012 May; 413(9-10):861-8. PubMed ID: 22309680
[TBL] [Abstract][Full Text] [Related]
7. Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based nontargeted and targeted analyses.
Lu X; Li Y; Xia B; Bai Y; Zhang K; Zhang X; Xie H; Sun F; Hou Y; Li K
Int J Cancer; 2019 Apr; 144(8):2033-2042. PubMed ID: 30114318
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.
Xie H; Hou Y; Cheng J; Openkova MS; Xia B; Wang W; Li A; Yang K; Li J; Xu H; Yang C; Ma L; Li Z; Fan X; Li K; Lou G
Oncotarget; 2017 May; 8(19):32134-32146. PubMed ID: 28389631
[TBL] [Abstract][Full Text] [Related]
9. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
10. Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.
Garg G; Yilmaz A; Kumar P; Turkoglu O; Mutch DG; Powell MA; Rosen B; Bahado-Singh RO; Graham SF
Metabolomics; 2018 Nov; 14(12):154. PubMed ID: 30830441
[TBL] [Abstract][Full Text] [Related]
11. Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer.
Chen J; Zhang X; Cao R; Lu X; Zhao S; Fekete A; Huang Q; Schmitt-Kopplin P; Wang Y; Xu Z; Wan X; Wu X; Zhao N; Xu C; Xu G
J Proteome Res; 2011 May; 10(5):2625-32. PubMed ID: 21456628
[TBL] [Abstract][Full Text] [Related]
12. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
[TBL] [Abstract][Full Text] [Related]
13. Large-scale profiling of metabolic dysregulation in ovarian cancer.
Ke C; Hou Y; Zhang H; Fan L; Ge T; Guo B; Zhang F; Yang K; Wang J; Lou G; Li K
Int J Cancer; 2015 Feb; 136(3):516-26. PubMed ID: 24895217
[TBL] [Abstract][Full Text] [Related]
14. Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS).
Li J; Wang Z; Liu W; Tan L; Yu Y; Liu D; Wei Z; Zhang S
Cancer Biomark; 2023; 37(2):67-84. PubMed ID: 37248885
[TBL] [Abstract][Full Text] [Related]
15. Metabolic phenotyping for monitoring ovarian cancer patients.
Ke C; Li A; Hou Y; Sun M; Yang K; Cheng J; Wang J; Ge T; Zhang F; Li Q; Li J; Wu Y; Lou G; Li K
Sci Rep; 2016 Mar; 6():23334. PubMed ID: 26996990
[TBL] [Abstract][Full Text] [Related]
16. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
17. Exploring the prognostic significance of preoperative high normocalcemia in epithelial ovarian carcinoma.
Cho HW; Ouh YT; Hong JH; Lee JK
Arch Gynecol Obstet; 2021 Mar; 303(3):803-810. PubMed ID: 33078229
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
Pylväs-Eerola M; Karihtala P; Puistola U
BMC Cancer; 2015 Jul; 15():493. PubMed ID: 26134400
[TBL] [Abstract][Full Text] [Related]
19. Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
Kawakami E; Tabata J; Yanaihara N; Ishikawa T; Koseki K; Iida Y; Saito M; Komazaki H; Shapiro JS; Goto C; Akiyama Y; Saito R; Saito M; Takano H; Yamada K; Okamoto A
Clin Cancer Res; 2019 May; 25(10):3006-3015. PubMed ID: 30979733
[TBL] [Abstract][Full Text] [Related]
20. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.
Fan L; Zhang W; Yin M; Zhang T; Wu X; Zhang H; Sun M; Li Z; Hou Y; Zhou X; Lou G; Li K
Acta Oncol; 2012 Apr; 51(4):473-9. PubMed ID: 22283470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
